Cimacef (cefuroxime) 1.5 g. vial intravenous №1


Manufacturer: Ukraine



Treatment of infections caused by microorganisms sensitive to cefuroxime, or therapy in the period before determining the pathogen of the infectious disease.

Infectious diseases of the respiratory tract: acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative chest infections;

infectious diseases of the throat and nose: sinusitis, tonsillitis, pharyngitis;

infectious diseases of the urinary tract: acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria;

infectious diseases of soft tissues: cellulitis, erysipeloid, wound infections;

infectious diseases of bones and joints: osteomyelitis, septic arthritis;

infections in obstetrics and gynecology: infectious and inflammatory diseases of the pelvic organs;

gonorrhea, especially in cases where penicillin is contraindicated;

other infectious diseases, including septicaemia and meningitis.

Prevention of infectious complications after operations on the chest and abdomen, operations on the pelvic organs, vascular, cardiovascular and orthopedic operations.

In most cases, monotherapy with Kimacef is effective, but if necessary, the drug can be used in combination with aminoglycoside antibiotics or metronidazole (orally, in suppositories or by injection).

In the case of an existing or expected mixed aerobic and anaerobic infection (for example, peritonitis, aspiration pneumonia, lung abscess, pelvic organs and brain) and a high probability of such infection (for example, in operations on the large intestine and in gynecological surgery), the use of the drug Kimacef in combination with metronidazole is acceptable.

In the treatment of pneumonia and exacerbation of chronic bronchitis, the drug Kimacef can be prescribed before oral administration of cefuroxime axetil, when necessary.